Pune, May 19, 2023 (GLOBE NEWSWIRE) -- A global Healthcare research and business consulting firm, Maximize Market Research, has published a market intelligence report on the “Retinitis Pigmentosa Market”. The report is a combination of primary data and secondary data and domain experts have analyzed the Retinitis Pigmentosa Market from a local as well as a global point of view. Over the forecast period, Maximize Market Research expects the market to grow from USD 12.1 Bn in 2022 to USD 20.47 Bn in 2029 at a CAGR of 7.8 percent.
Retinitis Pigmentosa Market Report Scope and Research Methodology
| Market Size in 2022 | USD 12.1 Bn. |
| Market Size in 2029 | USD 20.47 Bn. |
| CAGR | 7.8 percent (2023-2029) |
| Forecast Period | 2023-2029 |
| Base Year | 2022 |
| Number of Pages | 276 |
| No. of Tables | 113 |
| No. of Charts and Figures | 112 |
| Segment Covered | Type, Treatment, Route of Administration, Diagnosis, End-Users and Distribution Channel |
| Regional Scope | North America, Europe, Asia Pacific, Middle East and Africa, South America |
| Report Coverage | Market Share, Size & Forecast by Revenue | 2022−2029, Market Dynamics, Growth Drivers, Restraints, Investment Opportunities, and Key Trends, Competitive Landscape, Key Players Benchmarking, Competitive Analysis, MMR Competition Matrix, Competitive Leadership Mapping, Global Key Players’ Market Ranking Analysis. |
Request For Free Sample Report : https://www.maximizemarketresearch.com/request-sample/187773
The Retinitis Pigmentosa Market report uses a bottom-up approach to estimate the market size by value and volume. The report includes growth hubs, investment feasibility, restraints and competitive analysis of the market in five major geographic regions such as North America, Asia Pacific, Middle East and Africa, Europe and South America. The report presents a market analysis through segments along with its multiple sub-segments. The report involves data regarding mergers and acquisitions and partnerships by major key companies. The market data has been collected through primary and secondary research methods. Collected data is later analyzed by tools such as SWOT, PORTER’s five force model and PESTLE analysis which provides political, social, economic, environmental, technological and legal aspects of the market.
Retinitis Pigmentosa Market Overview
Retinitis pigmentosa is a group of eye problems that can affect the retina and reduces the natural response of the retina to light and making it hard to see. Retinitis Pigmentosa is a genetic condition and is expected to pass down in the next generations. These are the primary causes of the Retinitis Pigmentosa Market. A loss of night vision and central vision, gradual loss of side vision and color vision are some of the symptoms of Retinitis Pigmentosa.
Retinitis Pigmentosa Market Dynamics
The growing number of gene mutations and inherited disorders is expected to increase the chances of retinitis pigmentosa. The marriage between the same clowns is also expected to increase the genetic mutations in the next generation and cause retinitis pigmentosa. These factors are expected to drive the Retinitis Pigmentosa Market. Recently, Cedars-Sinai investigators are started developing a way to treat retinitis pigmentosa by using engineered stem cells. The new approach of using cells derived from human induced pluripotent stem cells (iPSCs), which are renewable and scalable and also can delay the progression of this neurodegenerative disease in rodents. These recent developments are expected to drive the Retinitis Pigmentosa Market Growth.
New retinitis pigmentosa treatments such as gene therapies for X-linked retinitis pigmentosa, correcting errors in the USH2A gene, treating leber congenital amaurosis and corrections in the RHO gene are also expected to boost the Retinitis Pigmentosa Market. The government healthcare institutions along with private organizations investing in the healthcare sector to expand awareness and research regarding retinitis pigmentosa. These factors are expected to stimulate the major Retinitis Pigmentosa Key Players to invest in the market to increase their Retinitis Pigmentosa Market Share. But, the availability of limited treatment options for retinitis pigmentosa and the lack of skilled personnel are expected to limit the growth of the Retinitis Pigmentosa Market.
Get a Sample Copy of the Report : https://www.maximizemarketresearch.com/request-sample/187773
Retinitis Pigmentosa Market Regional Insights
North America dominated the retinitis pigmentosa market in 2022 and is expected to hold the largest revenue share during the forecast period. The presence of major Retinitis Pigmentosa Key Companies and the highest healthcare expenditure among all regions in North America has been driving the region’s Retinitis Pigmentosa Market. Also, the United States has the highest prevalence of retina disorders, which is one of the major drivers in the regional market.
Asia Pacific is the second-largest growing region with the highest CAGR in the Retinitis Pigmentosa Market during the forecast period (2023-2029). The growing population and the patients with retina disorders seeking costlier treatments and countries such as India and China are adopting advanced treatment technologies and the growth in the healthcare infrastructure is expected to drive the Asia Pacific Retinitis Pigmentosa Market.
Retinitis Pigmentosa Market Segmentation
By Type:
- Autosomal Recessive
- Autosomal Dominant
- X-Linked
By Treatment:
- Vitamin A
- Docosahexaenoic acid (DHA)
- Calcium channel blockers
- Gene therapy
- Retinal eye prosthetics
- Others
In 2022, Vitamin A dominated the Retinitis Pigmentosa market and is expected to continue its dominance over the forecast period. There are does not have standard treatments for the patient, which suffer from Retinitis Pigmentosa disorder.
By Route of Administration:
- Oral
- Topical
- Others
The oral route of administration had the largest revenue in 2022. The oral administration route is more effective in reducing the central muscular thickness and improving visual acuity (VA) in RP-CME patients.
Get Customization on this Report for Specific Research Solutions: https://www.maximizemarketresearch.com/request-customization/187773
By Diagnosis:
- Electroretinogram
- Visual Field Testing
- Genetic Testing
- Others
By End-Users:
- Hospitals
- Specialty Clinics
- Homecare
- ophthalmologist
- Others
By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Retinitis Pigmentosa Key Competitors include:
- Bausch Health Companies Inc. (Canada)
- MeiraGTx Limited (US)
- Novartis AG (Switzerland)
- Sun Pharmaceutical Industries Ltd. (India)
- Allergan (Ireland)
- Astellas Pharma Inc. (Japan)
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
- Orphagen Pharmaceuticals, Inc (US)
- Clino Corporation (Japan)
- Spark Therapeutics, Inc (US)
- Caladrius Biosciences, Inc. (US)
- Genethon (France)
- Gensight Biologics(France)
- Grupo Ferrer International, S.A. (Spain)
- Nanovector S.r.l (Italy)
- Mimetogen Pharmaceuticals Inc. (Canada)
- Ionis Pharmaceuticals, Inc. (US)
- AGTC (US)
- ReNeuron Group plc (UK)
- ProQR Therapeutics. (Netherlands)
Get the Sample PDF of Report: https://www.maximizemarketresearch.com/request-sample/187773
Key questions answered in the Retinitis Pigmentosa Market are:
- What is a Retinitis Pigmentosa?
- What was the Retinitis Pigmentosa Market Size in 2022?
- What is the expected Retinitis Pigmentosa Market size during the forecast period?
- What are the global trends in the Retinitis Pigmentosa Market?
- What are the major restraints for the Retinitis Pigmentosa Market?
- Which segment dominated the Retinitis Pigmentosa Market growth?
- What is the demand pattern for the Retinitis Pigmentosa Market?
- What growth strategies are the players considering to increase their presence in Retinitis Pigmentosa Market?
- What are the upcoming industry applications and trends for the Retinitis Pigmentosa Market?
- Who are the leading companies and what are their portfolios in Retinitis Pigmentosa Market?
- Which region dominates the largest market share in Retinitis Pigmentosa Market?
Key Offerings:
- Past Market Size and Competitive Landscape (2018 to 2021)
- Past Pricing and price curve by region (2018 to 2021)
- Market Size, Share, Size & Forecast by different segment | 2022−2029
- Market Dynamics – Growth Drivers, Restraints, Opportunities, Organization Size, Application and Industry Vertical
- Market Segmentation – A detailed analysis by Type, Treatment, Route of Administration, Diagnosis, End-Users and Distribution Channel
- Competitive Landscape – Profiles of selected key players by region from a strategic perspective
- Competitive landscape – Market Leaders, Market Followers, Regional player
- Competitive benchmarking of key players by region
- PESTLE Analysis
- PORTER’s analysis
- Value chain and supply chain analysis
- Legal Aspects of Business by region
- Lucrative business opportunities with SWOT analysis
- Recommendations
Maximize Market Research is leading Healthcare research firm, has also published the following reports:
Allogeneic Cell Therapy Market - The market size is expected to reach USD 1.72 Bn by 2029 at a CAGR of 24.5 percent during the forecast period. The market is expected to be driven by a wider range of patients who can be treated with allogeneic cell treatments irrespective of the patient's age, health status, or history of previous diseases.
Cytomegalovirus Retinitis Market - The market size is expected to reach USD 6.22 Mn by 2029 at a CAGR of 5.1 percent during the forecast period. The market is expected to be driven by expanding predominance of cytomegalovirus retinitis cases and improvement in medical facilities.
Rett Syndrome Market - The market size is expected to reach USD 515.06 Mn by 2029 at a CAGR of 10.23 percent during the forecast period. The market is expected to be driven by growing awareness about Rett syndrome Market among healthcare professionals, parents, and caregivers, there is a heightened focus on early diagnosis.
Chronic Lower Back Pain Market - The market size is expected to reach USD 13.42 Bn by 2029 at a CAGR of 5.39 percent during the forecast period. The market is expected to be driven by an increasingly sedentary lifestyle, where people lose their movement and are stuck in one position which harms the stature of the lower back.
Polyclonal Antibodies Market - The market size is expected to reach USD 2.05 Bn by 2029 at a CAGR of 5.2 percent during the forecast period. The market is expected to be driven by the rising prevalence of rare illnesses, increased healthcare spending in developed economies, and increased research and development activities.
About Maximize Market Research:
Maximize Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include Healthcare, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.
